anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The recommended dose of levocetirizine dihydrochloride for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in patients 6 months to 17 years of age is based on extrapolation of efficacy from adults 18 years of age and older [see Clinical Studies (14)].

The recommended dose of levocetirizine dihydrochloride in patients 6 months to 2 years of age for the treatment of the symptoms of perennial allergic rhinitis and 6 months to 11 years of age with chronic idiopathic urticaria is based on cross-study comparisons of the systemic exposure of levocetirizine dihydrochloride in adults and pediatric patients and on the safety profile of levocetirizine dihydrochloride in both adult and pediatric patients at doses equal to or higher than the recommended dose for patients 6 months to 11 years of age.

The safety of levocetirizine dihydrochloride 5 mg once daily was evaluated in 243 pediatric patients 6 to 12 years of age in two placebo-controlled clinical trials lasting 4 and 6 weeks. The safety of levocetirizine dihydrochloride 1.25 mg twice daily was evaluated in one 2-week clinical trial in 114 pediatric patients 1 to 5 years of age and the safety of levocetirizine dihydrochloride 1.25 mg once daily was evaluated in one 2-week clinical trial in 45 pediatric patients 6 to 11 months of age  [see Adverse Reactions (6.1)].

The effectiveness of levocetirizine dihydrochloride 1.25 mg once daily (6 months to 5 years of age) and 2.5 mg once daily (6 to 11 years of age) for the treatment of the symptoms of perennial allergic rhinitis and chronic idiopathic urticaria is supported by the extrapolation of demonstrated efficacy of levocetirizine dihydrochloride 5 mg once daily in patients 12 years of age and older based on the pharmacokinetic comparison between adults and children.

Cross-study comparisons indicate that administration of a 5 mg dose of levocetirizine dihydrochloride to 6 to 12 year old pediatric patients resulted in about 2-fold the systemic exposure (AUC) observed when 5 mg of levocetirizine dihydrochloride was administered to healthy adults. Therefore, in children 6 to 11 years of age the recommended dose of 2.5 mg once daily should not be exceeded. In a population pharmacokinetics study the administration of 1.25 mg once daily in children 6 months to 5 years of age resulted in systemic exposure comparable to 5 mg once daily in adults [see Dosage and Administration (2.2), Clinical Studies (14), and Clinical Pharmacology (12.3)].
This study will prospectively collect the tissue and blood samples of locally advanced esophageal cancer patients, perform CRT resistance biomarkers testing and functional imaging analysis including SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI before treatment, 2-3 weeks after the initiation of CRT, and 4 weeks post-nCRT. The investigators will use advanced statistical tools to establish the model and further validate the model in another group of patients. The investigators will also establish a model for survival prediction.
A method for expanding growth of hematopoietic stem cells in culture includes a step of admixing to the culture a TGF-.beta. antagonist such as a soluble TGF-.beta. receptor or a TGF-.beta.-neutralizing antibody. Also, treating an animal includes steps of admixing a TGF-.beta. antagonist to a culture of bone marrow cells to stimulate production of hematopoietic stem cells in the culture, and thereafter administering hematopoietic cells so produced to the animal. Also, a method for treating an animal includes steps of administering a TGF-.beta. antagonist to the animal.
US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
Participants allocated to this arm follow the usual routines of the out patient dementia clinic but are requested to have the serum level of the prescribed drug measured after 12 month. Also, CYP2D6, BcHE K and APOe4 status will be determined after 12 months.
The SpO2 TR width is set as the Standard TR. The median of the TR is shifted up compared to the Standard TR. The actual TR will vary depending on the GA, as is standard practice in the department.
Orthostatic hypotension, falls, and syncope have been reported in patients treated with the recommended duloxetine delayed-release capsules dosage. Syncope and orthostatic hypotension tend to occur within the first week of therapy but can occur at any time during DRIZALMA SPRINKLE treatment, particularly after dose increases. The risk of falling appears to be related to the degree of orthostatic decrease in blood pressure (BP) as well as other factors that may increase the underlying risk of falls.

In an analysis of patients from all placebo-controlled trials, patients treated with duloxetine delayed-release capsules reported a higher rate of falls compared to patients treated with placebo. Risk appears to be related to the presence of orthostatic decrease in BP. The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as anti-hypertensives) or are potent CYP1A2 inhibitors [see Warnings and Precautions (5.12) and Drug Interactions (7.1)] and in patients taking DRIZALMA SPRINKLE at doses above 60 mg daily. Consider dose reduction or discontinuation of DRIZALMA SPRINKLE in patients who experience symptomatic orthostatic hypotension, falls and/or syncope during DRIZALMA SPRINKLE therapy.

Risk of falling also appeared to be proportional to a patient’s underlying risk for falls and appeared to increase steadily with age. As geriatric patients tend to have a higher underlying risk for falls due to a higher prevalence of risk factors such as use of multiple medications, medical comorbidities and gait disturbances, the impact of increasing age by itself is unclear. Falls with serious consequences including fractures and hospitalizations have been reported with duloxetine delayed-release capsules use [see Adverse Reactions (6.1)].
In the prodn. of vaccines against feline panleukopenia virus pathogenic panleukopenia virus is passaged at least 80 times through cat kidney cells and then at least 18 times through permanent tissue cells of felids or mustelids, then the attenuated virus thus obtained increased on cat foetal cells and converted into a vaccine. Attenuated panleukopenia virus strain BW 103 is claimed. Used for immunisation for cats against panleukopenia (infectious gastoenteritis). The antigen is highly pure. Since the attenuated virus is raised on homologous tissues, allergic reactions to the vaccine are avoided. The method of raising the virus permits a product of uniform quality to be produced. The attenuated vaccine obtained gives more rapid protection than existing vaccines.
Hair is permanently waved by treating it with an agent which breaks the -S-S-bonds of the keratin, constraining the hair to a desired configuration and then treating it with a solution containing polythionate ions, preferably trithionate. tetrathionate or pentathionate ions and mixtures thereof.  The concentration of the polythionate ions in the neutralizing solution may amount to 1 gram molecule per litre and is preferably about 10 grams of potassium tetrathionate or an equimolecular quantity of sodium tetrathionate per 60 grams of hair.  The polythionate solution, which preferably has a pH of 7 or slightly on the acid side of neutrality, may also contain non-ionic, cationic or anionic surface active agents, e.g. cetyl-trimethyl ammonium bromide, sodium lauryl sulphate, lauryl trimethyl ammonium bromide or the monolauric ester of a polyethylene glycol containing 12 ethylene oxide residues, and softening agents for the hair, e.g. lanolin or cholesterol.  Specified reducing agents used to break the -S-S- bonds of the keratin are aqueous solutions of ammonium thioglycolate, thioglycolic acid, a -mercapto-acetamide, ammonium sulphite and sodium bisulphite, which may also contain ammonia, ammonium carbonate, urea, monoethanol amine, triethanolamine and ethyl alcohol.
The invention relates to an antibacterial tanshinone extract extracted from Salvia spp. roots, a preparation method thereof, application of the antibacterial tanshinone extract and products of the antibacterial tanshinone extract. The extract contains cryptotanshinone, dihydro-tanshinone, tanshinone I and tanshinone IIA, wherein the total weight content of the four compounds is 40 to 99 percent of the total weight content of the extract; the weight content of the cryptotanshinone is 50 to 95 percent of the total weight of the four compounds; the weight content of the dihydro-tanshinone is 5 to 30 percent of the total weight of the four compounds; the weight content of the tanshinone I is 0 to 20 percent of the total weight of the four compounds; and the weight content of the tanshinone IIA is 0 to 40 percent of the total weight of the four compounds. The preparation method comprises the steps of diacolation extraction and purification for two times. The extract is used for preparing antibacterial medicines or other products. The tanshinone extract obtained has high purity, more reasonable proportions of various compositions, and can exert better clinic effect.
FIELD: pharmacology. ^ SUBSTANCE: invention relates to the field of medicine immediately dealing with preparation of pharmaceutical compounds. Proposed is a compound that contains a solution composed of a synthetic peptide, its final concentration being no less than 70 mg/ml, mixed with polyethyleneglycol. The synthetic peptide is represented by a HIV [cell] FI. The polyethyleneglycol final concentration is no less than 10% and no more than 75% of the compound total mass. Additionally proposed is a reference dose compound that contains a synthetic peptide (HIV [cell] FI) water solution with the synthetic peptide final concentration no less than 70 mg/ml mixed with polyethyleneglycol, the latter's final concentration being no less than 10% and no more than 75% of the compound total mass The proposed composition compound provides for maintenance of improved solubility and stability levels during lengthier periods of time. ^ EFFECT: proposed is a method of HIV-infection therapy consisting in the HIV-infected patient receiving injection of the pharmaceutical compound in accordance with the invention concept. ^ 16 cl, 4 ex, 7 tbl, 1 ex
A variety of effective interventions exist for people who are willing to seek help for depression. However, there is a lack of interventions for individuals who are not willing to seek help or follow through with treatment recommendations. This is the first population-based intervention for depression that is appropriate for individuals in all stages of change-not merely the minority who are prepared to take action. Two primary care samples were included: 1) patients at risk for or experiencing depression but not involved in or planning treatment (Untreated Sample), and 2) patients newly prescribed antidepressant medication (Antidepressant Sample). Patients from both samples were randomly assigned to receive the intervention consisting of telephone assessments, a stage-based workbook, and three individualized, computer-generated reports mailed to the home (n=443), or usual care (n=459). Primary outcomes, assessed at 9 months, were change in depression severity, reliable and clinically significant change in depression severity, stage of change for using effective methods or prevent or reduce depression, onset of major depression if experiencing only subclinical symptoms at baseline, and medication adherence. The study design included an examination of whether the intervention effect was moderated by primary care sample, baseline use of effective methods to prevent or reduce depression, and level of depression.
The sample size was calculated according to the One-Sample Log-rank Test.During the treatment of amlotinib, metastatic site imaging was performed every 2-3 cycles, and the efficacy assessment and safety information were collected according to the RECIST version 1.1 criteria. After the completion of amlotinib treatment, survival follow-up was continued to clarify the survival status of the patients. When descriptive statistical analyses of clinicopathological characteristics were performed, categorical information was described by frequency counts and constitutive ratios, and quantitative information, such as conforming to normal distribution, was described by mean ± standard deviation, and not conforming to normal distribution, was described by median and interquartile spacing. Progression-free survival and overall survival at each time point were calculated by the Kaplan-Meier method and plotted as survival curves, Log-rank test was used to compare the prognostic differences between groups of latent variables, and the prognostic impact of latent variables on the anilotinib-treated patients was analysed using the COX regression risk model for exploratory analysis, and the risk ratios (hazard ratios (HRs) for quantitative evaluation. Variables with p-values less than 0.1 in the univariate COX regression analyses were screened by stepwise regression into the multivariate COX regression analyses. If the lapse rate exceeded 20%, sensitivity analyses were used to assess the impact of the lapse on the endpoint outcome event, which was performed by assuming a death outcome for the study subjects who were lost and analysing the endpoint event, and then treating the lost patients as normal and analysing the endpoint event and assessing the impact of the lost patients on the endpoint event. spss version 21.0 was used for the statistics, and a p\<0.05 was considered to be clinically significant.
The interventions for this study are non-invasive. For patients, routine pre-operative MRI that includes task based fMRI and perfusion data acquisition will be performed on a 3T scanner. Patients who participate in this study, will have approximately 5 minutes added to their scan time for the below described breath holding fMRI (BH fMRI) paradigm, which will be done for research purposes. For healthy volunteers, participation will involve having a high resolution anatomical MRI done with the same paradigms which patients will have, listed below. the total scanner time will be approximately 25 minutes, and the scan will not be billed to the healthy volunteer.
1. Food composition comprising an oil-in-water emulsion of triglyceride oils having a solid fat content at ambient to body temperature with a food emulsifier which is a lecithin or galactolipid based food emulsifier, wherein while using said food composition containing emulsion in an amount corresponding to 2-40 ml of triglyceride oils, gives a prolonged feeling of satiety. 2. Food composition according to claim 1, characterized in that it gives a fast coming of satiety, wherein the triglyceride oils are combined with palmkernel oil. 3. Food composition according to any of claims 1-2, wherein the triglyceride oils are selected from the group consisting of palm oil, cocoa butter and other confectionery fats. 4. Food composition according to any of claims 1-3, wherein the triglyceride oils are a fraction of palm oil. 5. Food composition according to claim 1-4, wherein the galactolipid based emulsifier is fractionated oat oil. 6. Food composition according to any of claims 1-5, wherein the mixture or the oil phase of the oil-in-water emulsion comprises 80-99 % by weight of triglyceride oils and 1-20 % by weight of 21 emulsifier. 7. Food composition according to any of claims 1-6, which is a dairy product comprising 1-30 % by weight, preferably 2-15 % by weight of the oil-in-water emulsion. 8. Food composition according to claim 7, comprising 4-10 % by weight of an emulsion of a triglyceride fraction of palm oil and fractionated oat oil is used as said galactolipid based food emulsifier. 9. Use of a mixture of triglyceride oils having a solid fat content at ambient to body temperature and a food emulsifier which is a lecithin or galactolipid based food emulsifier in aqueous solution in an amount corresponding to 2-40 ml of triglyceride oils as a food or for the preparation of a food composition according to any of claims 1-8 giving a prolonged feeling of satiety. 10. Use of a mixture of triglyceride oils having a solid fat content at ambient to body temperature and a food emulsifier which is a lecithin or galactolipid based food emulsifier in aqueous solution in an amount corresponding to 2-40 ml of triglyceride oils as a food or for the preparation of a food composition according to any of claims 1-8 for provide of reducing of consumption of calories, and particularly, of selective decreasing of following fat consumption. 11. Use of a mixture of triglyceride oils having a solid fat content at ambient to body temperature and a food emulsifier which is a lecithin or galactolipid based food emulsifier in aqueous solution in an amount corresponding to 2-40 ml of triglyceride oils for preparing of pharmaceutical composition for the prophylaxis and treatment of obesity, for the control of calorie or fat intake and for the prevention and treatment of cardiovascular diseases and diabetes.
Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
The longitudinal course of atopic dermatitis (AD) is heterogeneous and complex. While previously thought to be a childhood disorder, recent studies demonstrated that childhood-onset AD may take several different courses that may involve persistence into adulthood becoming a lifelong condition. Other patients only demonstrated adult-onset AD. Different factors may play a role in the timing of AD onset. Assessing the longitudinal course also involves understanding the changing temporal pattern of AD. Understanding the dynamic course of AD is important in identifying individualized treatment recommendations for patients.
Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not treatment-emergent small-cell neuroendocrine prostate cancer \[t-SCNC\]) who progressed on abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive cetrelimab 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
NEW MATERIAL:A physiologically active substance extracted from variolated tissues. Property; light yellowish brown amorphous hygroscopic powder. Solubility; soluble in water, methanol and acetone and insoluble in benzene and ether. pH; 6.5-7.5. Molecular weight; 1,000-20,000. Ultraviolet absorption; lambdamax 265-275nm. Color reaction; positive to amino acids, sugars and phosphorus and negative to proteins and phenol. USE:Having excellent inhibitory activity against formation of kallikrein and useful as an anti-inflammatory, analgesic, antiallergic agents, etc. PREPARATION:Variolated tissues (e.g. tissues infected and inflamed with vaccinia virus) are ground and an extracting solvent (e.g. distilled water) is added to remove the tissual pieces. The obtained extract is subsequently deproteinized and adsorbed on an adsorbent (e.g. active carbon). The adsorbed components are subsequently eluted and fractionation by molecular weight is carried out to afford the aimed substance.
Honokiol, a bioactive component found in Magnolia officinalis, has shown in protecting against ischemic stroke in animal models. However, its poor water solubility has limited its clinical applications. In this study, we introduced a hydrophilic building block on the aromatic ring of honokiol, resulting in the synthesis of four new compounds (HH-A, -B, -C and -D) with significantly improved water solubility. We then investigated the neuroprotective effects of these compounds in mouse and rat models of transient middle cerebral artery occlusion/reperfusion (tMCAO/R) brain injury. Among the compounds tested, HH-A, also known as (S)-6-((3',5-diallyl-2,4'-dihydroxy-[1,1'-biphenyl]-3-yl)amino)-6-oxohexane-1,5-diaminium chloride, showed the most promising results. HH-A was found to significantly reduced the infarct volume and brain edema in mice. It also outperformed the other three compounds and honokiol, even surpassing the effects of edaravone dexborneol. Additionally, HH-A demonstrated dose-dependent improvements in body weight, neurological deficits, and infarct volume. Further analysis in tMCAO/R rat model revealed that HH-A treatment led to significant upregulations of Nrf2 and HO-1 in the brain. HH-A also significantly reduced the expression of HNE, and exhibited anti-apoptotic effects by decreasing the expression of Bax and increasing the expression of Bcl-2. This was further supported by a decrease in the number of TUNEL positive cells. Taken together, the neuroprotective effects of HH-A may be attributed to its ability to target the Nrf2/HO-1 signaling pathway, leading to reduced oxidative stress and apoptosis in the brain. These findings suggest that HH-A has potential as a therapeutic agent for the treatment of ischemic stroke.
The LGIT diet of the experimental group consisted of 55% fat, 30% protein and 15% carbohydrate, and the glycemic index of the food was limited to less than 50. The meal was prepared by a public nutritionist who evaluated the nutritional composition of the inpatients provided by the canteen and then added or subsumed the compound nutrition powder.
PROBLEM TO BE SOLVED: To obtain a gel type skin detergent good in usability without adding a thickening agent inhibiting the foaming by combining a specific polyoxyethylene dlester with a specified anionic surfactant and an amphoteric surfactant. SOLUTION: This skin detergent is obtained by using (A) a polyoxyethylene diester of the formula [R is a saturated or a higher unsaturated aliphatic hydrocarbon; (n) is an integer of 6-16] with (B) an anionic surfactant (especially a sulfuric ester-based anionic surfactant) and an amphoteric surfactant in combination. Polyoxyethylene dlisostearate or polyoxyethylene dioleate or both are preferred. The skin detergent preferably has a gelled shape substantially without especially containing a thickening agent therein. The detergent has foaming functions in addition to makeup removing functions and provides a refreshing feeling in washing the bare skin. The blending ratio of the detergent is (2:1) to (1:8) expressed in terms of weight ratio and the total amount of both blended is within the range of 1-80wt.% based on the total amount of the detergent.
Methods and apparatus are provided for communication among display devices and sensor electronics unit in an analyte monitoring system. The analyte monitoring system may include a sensor that is configured to perform measurements indicative of analyte levels. The sensor may be communicatively coupled to the sensor electronics unit. The sensor electronics unit may be configured to transmit data indicative of analyte levels to the display devices using one or more communication protocols. Furthermore, the sensor electronics unit may be configured to operate in multiple modes, and switch between the modes in response to commands received from the display devices. Related systems, methods, and articles of manufacture are also described.